blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2150618

EP2150618 - IL-12 IMMUNOTHERAPY FOR CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.08.2018
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  08.09.2017
FormerGrant of patent is intended
Status updated on  04.09.2017
FormerExamination is in progress
Status updated on  09.08.2017
FormerGrant of patent is intended
Status updated on  20.03.2017
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): CY		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
University Health Network
R. Fraser Elliott Building, Room 1S-417 190 Elizabeth Street
Toronto, ON M5G 2C4 / CA
[2010/06]
Inventor(s)01 / MEDIN, Jeffrey, A.
251 Cocksfield Avenue
North York, Ontario M3H 3T6 / CA
02 / PAIGE, Christopher, J.
39 McKenzie Ave.
Toronto, Ontario M4W 1K1 / CA
 [2010/06]
Representative(s)Daniels, Jeffrey Nicholas, et al
Page White & Farrer Limited
Bedford House
21A John Street
London WC1N 2BF / GB
[N/P]
Former [2017/41]Daniels, Jeffrey Nicholas, et al
Page White & Farrer
Bedford House
John Street
London WC1N 2BF / GB
Former [2010/06]Hill, Christopher Michael, et al
Page White & Farrer Bedford House John Street
London, WC1N 2BF / GB
Application number, filing date08748251.905.05.2008
[2010/06]
WO2008CA00849
Priority number, dateUS20070916136P04.05.2007         Original published format: US 916136 P
[2010/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008134879
Date:13.11.2008
Language:EN
[2008/46]
Type: A1 Application with search report 
No.:EP2150618
Date:10.02.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 13.11.2008 takes the place of the publication of the European patent application.
[2010/06]
Type: B1 Patent specification 
No.:EP2150618
Date:11.10.2017
Language:EN
[2017/41]
Search report(s)International search report - published on:CA13.11.2008
(Supplementary) European search report - dispatched on:EP06.05.2011
ClassificationIPC:C12N15/867, A61K38/20, A61K39/00, A61K48/00, A61P35/00, A61P35/02, A61P37/04, C07K14/54, C12N15/24, C12N5/10, C12P21/02
[2010/06]
CPC:
A61K38/208 (EP,US); A61K35/545 (US); A61K39/00114 (US);
A61K39/4611 (EP); A61K39/4613 (EP); A61K39/46444 (EP);
A61K48/005 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P37/04 (EP); C07K14/5434 (US); C12N15/86 (EP,US);
C12N7/00 (US); A61K2039/515 (US); A61K2039/53 (US);
A61K2039/585 (US); A61K2239/31 (EP); A61K2239/38 (EP);
A61K2239/48 (EP); C07K2319/00 (US); C12N2710/16122 (US);
C12N2730/10122 (US); C12N2740/13043 (EP,US); C12N2740/15043 (US);
C12N2740/15071 (US); C12N2740/16022 (US); C12N2800/40 (US);
C12N2830/48 (US); C12N2830/60 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/41]
Former [2010/06]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:IL-12-IMMUNTHERAPIE GEGEN KREBS[2010/06]
English:IL-12 IMMUNOTHERAPY FOR CANCER[2010/06]
French:IMMUNOTHÉRAPIE DU CANCER AVEC L'IL-2[2010/06]
Entry into regional phase04.12.2009National basic fee paid 
04.12.2009Search fee paid 
04.12.2009Designation fee(s) paid 
04.12.2009Examination fee paid 
Examination procedure04.12.2009Examination requested  [2010/06]
21.10.2010Observations by third parties
01.12.2011Amendment by applicant (claims and/or description)
16.03.2012Despatch of a communication from the examining division (Time limit: M04)
26.07.2012Reply to a communication from the examining division
12.05.2014Despatch of a communication from the examining division (Time limit: M06)
24.11.2014Reply to a communication from the examining division
29.05.2015Despatch of a communication from the examining division (Time limit: M06)
08.12.2015Reply to a communication from the examining division
05.01.2016Despatch of a communication from the examining division (Time limit: M04)
05.05.2016Reply to a communication from the examining division
21.03.2017Communication of intention to grant the patent
31.07.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
31.07.2017Fee for grant paid
31.07.2017Fee for publishing/printing paid
04.09.2017Information about intention to grant a patent
04.09.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17184090.3  / EP3293266
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.03.2012
Opposition(s)12.07.2018No opposition filed within time limit [2018/38]
Fees paidRenewal fee
30.04.2010Renewal fee patent year 03
27.05.2011Renewal fee patent year 04
29.05.2012Renewal fee patent year 05
31.05.2013Renewal fee patent year 06
30.05.2014Renewal fee patent year 07
29.05.2015Renewal fee patent year 08
31.05.2016Renewal fee patent year 09
30.05.2017Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.05.2008
AT11.10.2017
CY11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
PT11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
TR11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
IE05.05.2018
LU05.05.2018
MT05.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
[2020/31]
Former [2020/27]HU05.05.2008
AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
PT11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
TR11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
IE05.05.2018
LU05.05.2018
MT05.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2020/16]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
TR11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
IE05.05.2018
LU05.05.2018
MT05.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2020/08]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
IE05.05.2018
LU05.05.2018
MT05.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/24]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
IE05.05.2018
LU05.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/19]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
IE05.05.2018
LU05.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/17]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
LU05.05.2018
CH31.05.2018
LI31.05.2018
Former [2019/12]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
CH31.05.2018
LI31.05.2018
Former [2019/06]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
MC11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/52]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SI11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/42]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
RO11.10.2017
SE11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/37]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
PL11.10.2017
SE11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/35]AT11.10.2017
CZ11.10.2017
DK11.10.2017
EE11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
SE11.10.2017
SK11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/24]AT11.10.2017
FI11.10.2017
HR11.10.2017
LT11.10.2017
LV11.10.2017
NL11.10.2017
SE11.10.2017
BG11.01.2018
NO11.01.2018
GR12.01.2018
IS11.02.2018
Former [2018/21]FI11.10.2017
LT11.10.2017
NL11.10.2017
NO11.01.2018
Former [2018/17]NL11.10.2017
Documents cited:Search[I]CA2253790  (PIZZOFERRATO EVA [CA]) [I] 6 * abstract * * page 11 ff. *;
 [X]  - PAJTASZ-PIASECKA E ET AL, "Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes.", FOLIA BIOLOGICA (PRAGUE), (2004), vol. 50, no. 1, ISSN 0015-5500, pages 7 - 14, XP002628036 [X] 10-16 * abstract * * page 8 * * page 11 - page 12 *
 [I]  - GAUTAM SUBHASH C ET AL, "Interleukin-12 (IL-12) gene therapy of leukemia: Immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells", CANCER GENE THERAPY, (200007), vol. 7, no. 7, ISSN 0929-1903, pages 1060 - 1068, XP002628037 [I] 6 * abstract * * page 1061 *

DOI:   http://dx.doi.org/10.1038/sj.cgt.7700201
 [I]  - PIZZOFERRATO E ET AL, "Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12.", HUMAN GENE THERAPY 10 DEC 1997 LNKD- PUBMED:9449375, (19971210), vol. 8, no. 18, ISSN 1043-0342, pages 2217 - 2228, XP002628038 [I] 6 * abstract * * page 2220 *

DOI:   http://dx.doi.org/10.1089/hum.1997.8.18-2217
 [AD]  - SATO TAKEYA ET AL, "Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY MAY 2007 LNKD- PUBMED:17375075, (20070320), vol. 15, no. 5, ISSN 1525-0016, pages 962 - 970, XP002628039 [AD] 3,4 * page 962 *

DOI:   http://dx.doi.org/10.1038/MT.SJ.6300122
 [A]  - QIAN CHENG ET AL, "Gene therapy of cancer: induction of anti-tumor immunity.", CELLULAR & MOLECULAR IMMUNOLOGY APR 2004 LNKD- PUBMED:16212896, (200404), vol. 1, no. 2, ISSN 1672-7681, pages 105 - 111, XP002628040 [A] 1-16 * page 106 *
 [A]  - BRECKPOT K ET AL, "Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics", GENE THERAPY, (20070322), vol. 14, no. 11, ISSN 0969-7128, pages 847 - 862, XP002628041 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.gt.3302947
 [A]  - CHANG ALEX H ET AL, "The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY MAR 2007 LNKD- PUBMED:17228317, (200703), vol. 15, no. 3, ISSN 1525-0024, pages 445 - 456, XP002628042 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1038/SJ.MT.6300060
 [A]  - OBANA S ET AL, "INDUCTION OF ANTI-TUMOR IMMUNITY BY MOUSE TUMOR CELLS TRANSFECTED WITH MOUSE INTERLEUKIN-12 GENE", JAPANESE JOURNAL OF MEDICAL SCIENCE AND BIOLOGY, TOKYO, JP, (19950101), vol. 48, ISSN 0021-5112, pages 221 - 236, XP008046187 [A] 1-16 * abstract * * page 232 * * figure 1 *
 [A]  - COLOMBO MARIO P ET AL, "Amount of interleukin 12 available at the tumor site is critical for tumor regression", CANCER RESEARCH, (1996), vol. 56, no. 11, ISSN 0008-5472, pages 2531 - 2534, XP002628043 [A] 1-16 * abstract *
 [A]  - MAZZOLINI GUILLERMO ET AL, "Gene therapy of cancer with interleukin-12", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, (20030901), vol. 9, no. 24, ISSN 1381-6128, pages 1981 - 1991, XP009145770 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.2174/1381612033454261
 [AD]  - LABBE ALAIN ET AL, "Murine model of immune-mediated rejection of the acute lymphoblastic leukemia 70Z/3.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAY 2006 LNKD- PUBMED:16622003, (20060501), vol. 176, no. 9, ISSN 0022-1767, pages 5354 - 5361, XP002628044 [AD] 1-16 * the whole document *
 [T]  - LABBE ALAIN ET AL, "IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy.", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE AUG 2009 LNKD- PUBMED:18624776, (200908), vol. 13, no. 8B, ISSN 1582-4934, pages 1962 - 1976, XP002628045

DOI:   http://dx.doi.org/10.1111/J.1582-4934.2008.00412.X
International search[X]  - CHEN X. ET AL., "Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells", RETROVIROLOGY, (20041101), vol. 1, no. 1, pages 37 - 49, XP021010209

DOI:   http://dx.doi.org/10.1186/1742-4690-1-37
 [X]  - KUWATA T. ET AL., "Construction of chimeric simian and human immunodeficiency viruses that produce interleukin 12", AIDS RESEARCH AND HUMAN RETROVIRUSES, (20000301), vol. 16, no. 5, pages 465 - 470, XP008123770
 [X]  - TAHARA H. ET AL., "Effective eradication of established murine tumors with Il-12 gene therapy using a polycistronic retroviral vector", JOURNAL OF IMMUNOLOGY, (1995), vol. 154, no. 12, pages 6466 - 6474, XP002049440
 [X]  - MILLER G. ET AL., "Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity", THE FASEB JOURNAL, (200304), vol. 17, no. 6, pages 728 - 730, XP008123798

DOI:   http://dx.doi.org/10.1096/FJ.02-0900FJE
 [X]  - MEKO J.B. ET AL., "High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12", CANCER RESEARCH, (19951101), vol. 55, pages 4765 - 4770, XP009116168
 [A]  - SUZUKI T. ET AL., "Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells", CLINICAL CANCER RESEARCH, (20050101), vol. 11, no. 1, pages 58 - 66, XP008132916
 [A]  - ZITVOGEL ET AL., "Construction and characterization of retroviral vectors expressing biologically active human interleukin-12", HUMAN GENE THERAPY, (199412), vol. 5, pages 1493 - 1506, XP000575529
 [A]  - ROBERTSON M.J. ET AL., "Interleukin 12: basic biology and potential applications in cancer treatment", THE ONCOLOGIST, (19960201), vol. 1, no. 1 & 2, pages 88 - 97, XP008123771
by applicantUS5240846
 US5399346
 US5436146
 US5529774
 US5547932
 US5639642
 US5645829
 US5656465
 US5670488
 US5672344
 US5741486
 US5830880
 US5854019
 US5869040
 US5910488
 US5911983
 US5928214
 US2007059275
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - KANAZAWA T; MIZUKAMI H; OKADA T; HANAZONO Y; KUME A; NISHINO H; TAKEUCHI K; KITAMURA K; ICHIMURA K; OZAWA K, "Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice", GENE THER., (200301), vol. 10, no. 1, pages 51 - 58
    - FUKUI T; HAYASHI Y; KAGAMI H; YAMAMOTO N; FUKUHARA H; TOHNAI; UEDA M; MIZUNO M; YOSHIDA J, "Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector", ORAL ONCOL., (200104), vol. 37, no. 3, doi:doi:10.1016/S1368-8375(00)00093-2, pages 211 - 215, XP004286757

DOI:   http://dx.doi.org/10.1016/S1368-8375(00)00093-2
    - LU, X. ET AL., JOURNAL OF GENE MEDICINE, (2004), vol. 6, pages 963 - 973
    - PANOSKALTSIS-MORTARI; RON T. MCELMURRY; SCOTT K. BELL; DARIO A.A. VIGNALI; MARTIN D. RYAN; ANDREW C. WILBER; R. SCOTT MCIVOR; JAKU, BLAZAR. MOLECULAR THERAPY, (2005), vol. 12, no. 3, pages 569 - 574
    - SZYMCZAK AL; VIGNALI DA, "Development of 2A peptide-based strategies in the design of multicistronic vectors", EXPERT OPIN BIOL THER., (2005), vol. 5, no. 5, doi:doi:10.1517/14712598.5.5.627, pages 627 - 638, XP055378453

DOI:   http://dx.doi.org/10.1517/14712598.5.5.627
    - SZYMCZAK AL; WORKMAN CJ; WANG Y; VIGNALI KM; DILIOGLOU S; VANIN EF; VIGNALI DA, "Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector", NAT BIOTECHNOL., (2004), vol. 22, no. 5, doi:doi:10.1038/nbt957, pages 589 - 594, XP002369309

DOI:   http://dx.doi.org/10.1038/nbt957
    - GOEDDEL, Gene Expression Technology: Methods in Enzymology, ACADEMIC PRESS, (1990), vol. 185
    - REMINGTON'S, Pharmaceutical Sciences, MACK PUBLISHING COMPANY
    - CASSIAN YEE, "Adoptive T cell therapy: Addressing challenges in cancer immunotherapy", J TRANSLATIONAL MEDICINE, (2005), vol. 3, no. 17
    - "Gene Therapy Clinical Trials Worldwide online database maintained by the Journal of Gene Medicine", GENE THERAPY CLINICAL TRIALS NUMBERS QUERY SEARCH, (2007), URL: hftp://www.wiley.co.uk/genetherapy
 US20060559757
 US20080052565
other   - PIZZOFFERATO,E, ET AL, "Enhanced immunogenicity of B Cell Lymphoma Genetically Engineered to Express Both B7-1 and Interleukin-12", HUMAN GENE THERAPY, (19971210), vol. 8, pages 2217 - 2228, XP002628038

DOI:   http://dx.doi.org/10.1089/hum.1997.8.18-2217
    - PIZZAFERRATO,E., "B7-2 Expression Above A Threshold Elicits Anti-Tumor Immunity As Effective As Interleukin-12 And Prolongs Survival In Murine B-Cell Lymphoma", INT.J.CANCER, PITTSBURGH, PA, USA, (2004), vol. 110, pages 61 - 69, XP003028068

DOI:   http://dx.doi.org/10.1002/ijc.20085
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.